| Literature DB >> 35540474 |
H K Kumara1, R Suhas1, D M Suyoga Vardhan1, M Shobha1, D Channe Gowda1.
Abstract
The present investigation involves the synthesis and spectroscopic and biological activity studies of the bis-hydrazones of quinazolinones derived from aspartic acid and glutamic acid. The antioxidant activities of the compounds were evaluated using DPPH, DMPD and ABTS radical scavenging assays whose results revealed that the IC50 of compounds 6, 7, 11, 12, 20, 21, 25 and 26 was lower than those of the standard references. The anti-inflammatory activity was evaluated with a haemolysis assay using a human blood erythrocytes suspension and the results demonstrated that compounds 8, 9, 13, 14, 22, 23, 27 and 28 were excellent anti-inflammatory agents. In addition, the antibacterial and antifungal activities against various clinical pathogens of human origin revealed that compounds 7, 9, 12, 14, 21, 23, 26 and 28 possessed potent antimicrobial properties. Furthermore, to understand the correlation between biological activity and drug-receptor interaction, molecular docking was performed on the active sites of tyrosine kinase (PDB ID: 2HCK), cyclooxygenase-2 (PDB ID: 1CX2) and glucosamine-6-phosphate (GlcN-6-P) synthase (PDB ID: 2VF5) which showed good binding profiles with the targets that can potentially hold the title compounds. The correlation study revealed that compounds containing EDGs (-OH, -OCH3) were excellent antioxidants, compounds with EWGs (-Cl, -NO2) exhibited good anti-inflammatory activity and compounds bearing -OH and -NO2 groups were very good antimicrobials. This journal is © The Royal Society of Chemistry.Entities:
Year: 2018 PMID: 35540474 PMCID: PMC9078910 DOI: 10.1039/c8ra00531a
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1The structures of the biologically active quinazolinone-hydrazones.
Scheme 1Bis-hydrazones of quinazolinone derived from anionic amino acid linkers. Reagents and conditions: (i) NMM, EDCI/HOBt, 0 °C to rt, (ii) NH2NH2·H2O, ethanol, reflux, 16 h, (iii) R–CHO, EtOH, reflux, 7–8 h.
Antioxidant activity and docking studies of the synthesized quinazolinone derivativesa
| Entry | Antioxidant activity | Molecular docking studies with | |||||
|---|---|---|---|---|---|---|---|
| DPPH, IC50 (μg mL−1) | DMPD, IC50 (μg mL−1) | ABTS, IC50 (μg mL−1) | Docking score | H-bond interactions with AA | π-cation interactions | π–π stacking interactions | |
| 1 | >300 | 280 ± 5.23 | 290 ± 3.26 | −3.865 | Arg 136 | Arg 76 | NF |
| 2 | 260 ± 3.56 | >300 | >300 | −4.047 | NF | NF | NF |
| 3 | 250 ± 2.21 | 240 ± 1.35 | 180 ± 1.65 | −4.545 | Ala 96 | NF | NF |
| 4 | 190 ± 1.40 | >300 | 240 ± 1.32 | −4.606 | Ala 96, Asn 46 | NF | NF |
| 5 | 85 ± 0.95 | 100 ± 1.56 | 70 ± 1.45 | −6.250 | Asn 46 | NF | NF |
| 6 | 50 ± 0.45 | 55 ± 0.56 | 45 ± 1.20 | −7.770 | Ala 96, Asn 46 | NF | NF |
| 7 | 35 ± 0.65 | 40 ± 0.72 | 25 ± 0.95 | −9.375 | Asp 73, Asp 73, Asn 46 | Arg 76 | NF |
| 8 | 120 ± 1.26 | 140 ± 2.36 | 150 ± 0.68 | −5.066 | Arg 76, Arg 136 | NF | NF |
| 9 | 180 ± 0.65 | 160 ± 0.65 | 145 ± 1.98 | −5.983 | Arg 136 | NF | NF |
| 10 | 70 ± 0.65 | 95 ± 1.67 | 100 ± 1.85 | −6.193 | NF | NF | NF |
| 11 | 50 ± 1.01 | 55 ± 0.98 | 45 ± 0.89 | −7.779 | Arg 136 | Arg 76 | NF |
| 12 | 25 ± 0.26 | 30 ± 0.65 | 40 ± 0.65 | −9.007 | Asp 73, Asp 73, Asn 46 | NF | Arg 136 |
| 13 | 150 ± 3.26 | 135 ± 1.69 | 160 ± 1.98 | −5.390 | Arg 136, Asn 46 | NF | NF |
| 14 | 180 ± 2.10 | 170 ± 0.98 | 155 ± 1.69 | −5.797 | Arg 136, Asn 46 | NF | NF |
| 15 | 260 ± 3.65 | >300 | 285 ± 2.65 | −3.865 | Arg 136, Gly 77 | NF | NF |
| 16 | >300 | 260 ± 3.45 | >300 | −4.188 | NF | NF | NF |
| 17 | 240 ± 2.98 | 225 ± 1.65 | 250 ± 3.56 | −4.582 | Ala 96, Asn 46, Gly 117 | NF | NF |
| 18 | >300 | 245 ± 2.56 | 280 ± 2.45 | −4.606 | Ala 96, Gly 117 | NF | NF |
| 19 | 95 ± 0.95 | 80 ± 1.20 | 75 ± 0.56 | −6.149 | Arg 136 | NF | NF |
| 20 | 45 ± 0.88 | 55 ± 0.75 | 40 ± 0.45 | −7.983 | NF | NF | NF |
| 21 | 30 ± 0.23 | 35 ± 0.98 | 35 ± 0.69 | −9.256 | Arg 136, Asp 49, Asp 49, Glu 42, Glu 42 | Arg 76 | Arg 76 |
| 22 | 150 ± 2.23 | 120 ± 2.45 | 135 ± 1.90 | −5.416 | Arg 136, Asn 46 | NF | NF |
| 23 | 200 ± 2.48 | 220 ± 1.65 | 205 ± 1.98 | −5.129 | NF | NF | NF |
| 24 | 75 ± 1.45 | 80 ± 1.70 | 100 ± 1.65 | −6.132 | Arg 136 | NF | NF |
| 25 | 35 ± 0.68 | 45 ± 1.20 | 50 ± 1.95 | −8.097 | Glu 50 | NF | NF |
| 26 | 25 ± 0.24 | 30 ± 0.50 | 45 ± 0.64 | −9.510 | Arg 136, Asp 73, Asp73, Glu 42 | Arg 76 | NF |
| 27 | 135 ± 1.98 | 150 ± 2.25 | 160 ± 1.40 | −5.309 | Asn 46, Glu 117 | NF | NF |
| 28 | 165 ± 0.65 | 140 ± 2.50 | 130 ± 2.60 | −4.973 | Arg 136 | NF | NF |
| AA | 50 ± 1.33 | 55 ± 2.26 | 45 ± 1.65 | −6.499 | Asp 73, Val 71 | NF | NF |
| GA | 60 ± 1.46 | 65 ± 1.26 | 50 ± 0.36 | −6.397 | Asp 73 | NF | NF |
The values are the means of three determinations, the ranges of which are <5% of the mean in all cases.
Amino acid; NF: not formed, AA = ascorbic acid, GA = gallic acid.
Anti-inflammatory activity and docking studies of the synthesized quinazolinone derivativesa
| Entry | Anti-inflammatory activity, IC50 (μg mL−1) | Molecular docking studies with | ||||
|---|---|---|---|---|---|---|
| Docking score | H-bond interactions with AA | Electrostatic forces of attraction | π-cation interactions | π–π stacking interactions | ||
| 1 | 270 ± 4.25 | −4.164 | Lys 118 | NF | NF | NF |
| 2 | >300 | −4.199 | Lys 118 | NF | NF | Phe 30 |
| 3 | 225 ± 2.69 | −3.905 | Lys 118 | NF | NF | NF |
| 4 | >300 | −4.068 | Lys 118 | NF | NF | Phe 30 |
| 5 | 100 ± 2.60 | −4.678 | NF | NF | NF | Phe 30, Phe 30 |
| 6 | 75 ± 1.50 | −4.879 | Asp, 87, Lys 118 | NF | NF | NF |
| 7 | 80 ± 2.06 | −4.976 | Ala 161, Asp 90, Asp 90, Asp 120, Asp 120, Lys 118 | NF | NF | Phe 30 |
| 8 | 45 ± 0.25 | −8.576 | NF | NF | NF | Phe 30 |
| 9 | 25 ± 0.56 | −8.908 | Cys 20, Lys 118, Lys 118 | Asp 13, Asp 87, Lys 118, Lys 118 | NF | Tyr 34 |
| 10 | 120 ± 1.40 | −4.810 | Lys 118, Asp 87 | NF | NF | Phe 30 |
| 11 | 80 ± 1.50 | −4.759 | NF | NF | NF | NF |
| 12 | 65 ± 1.60 | −4.719 | Ala 161, Asp 120, Asp 120, Glu 32, Glu 32, | NF | Lys 118 | Phe 30 |
| 13 | 50 ± 2.95 | −7.810 | Asp 87 | NF | NF | His 126, Phe 30 |
| 14 | 45 ± 1.28 | −8.027 | Asp 87, Cys 20, Lys 118, Ser 88 | Asp 13, Asp 87, Asp 90, Lys 118 | NF | NF |
| 15 | 270 ± 2.90 | −3.799 | Lys 118, Gly 17 | NF | NF | NF |
| 16 | >300 | −3.850 | Lys 118 | NF | NF | NF |
| 17 | 240 ± 3.40 | −4.116 | Asp 120, Lys 118, Lys 162 | NF | Lys 118 | NF |
| 18 | 260 ± 2.75 | −3.630 | Asp 87, Lys 118, Thr 127 | NF | NF | Phe 30 |
| 19 | 150 ± 2.35 | −4.378 | NF | NF | NF | NF |
| 20 | 80 ± 0.54 | −4.646 | NF | NF | Lys 118 | Phe 30 |
| 21 | 95 ± 0.45 | −4.506 | Asp 87, Asp 87, Asp 124, Lys 118, Lys 162, Lys 162 | NF | NF | NF |
| 22 | 50 ± 1.20 | −7.843 | Asp 87 | NF | NF | Phe 30 |
| 23 | 40 ± 0.64 | −8.023 | Asp 87, Asp 87, Lys 118 | Asp 13, Lys 118, Lys 162 | NF | Phe 30 |
| 24 | 115 ± 0.75 | −4.378 | Asp 87 | NF | NF | His 126 |
| 25 | 75 ± 0.80 | −4.482 | Asp 87 | NF | Lys 118 | Phe 30 |
| 26 | 90 ± 2.20 | −4.472 | Asp 87, Asp 87, Asp 90, Ser 88 | NF | NF | Phe 30 |
| 27 | 45 ± 0.90 | −8.143 | Asp 87, Lys 118 | NF | NF | Phe 30 |
| 28 | 35 ± 0.64 | −7.928 | Asp 87 | Tyr 34 | Lys 118 | Tyr 34 |
| IM | 55 ± 2.01 | −5.074 | NF | NF | Lys 118 | Phe 30 |
| IP | 50 ± 1.26 | - | - | - | - | - |
The values are the means of three determinations, the ranges of which are <5% of the mean in all cases.
Amino acid; NF: not formed; ‘-’: no activity/not analyzed, IM = indomethacin, IP = ibuprofen.
Antimicrobial activity and molecular docking studies of the synthesized analogues with 2VF5
| Entry | Antibacterial activity | Antifungal activity | Molecular docking studies with | ||||
|---|---|---|---|---|---|---|---|
| Docking score | Hydrogen bond interactions with amino acid residues | *π-cation interactions/#electrostatic forces of attraction | |||||
|
|
|
|
| ||||
| 1 | 04 ± 0.21 | 02 ± 0.32 | 05 ± 0.12 | 02 ± 0.41 | −6.150 | Ala 602, Glu 488, Ser 401 | *Lys 603 |
| 2 | 03 ± 0.38 | NA | 02 ± 0.35 | NA | −6.196 | Glu 488, Gly 301, Ser 401 | NF |
| 3 | 09 ± 0.65 | 07 ± 0.65 | 06 ± 0.65 | 04 ± 0.68 | −7.990 | Ala 602, Lys 603, Ser 347, Gln 348, Gln 348, Ser 303, Leu 346, Cys 300 | NF |
| 4 | 07 ± 0.45 | NA | 05 ± 0.38 | 03 ± 0.12 | −7.804 | Thr 302, Ser 401, Leu 346, Cys 300, Gln 348, Thr 352, Ser 303, Ser 347 | NF |
| 5 | 14 ± 0.32 | 10 ± 0.52 | 11 ± 0.42 | 09 ± 0.25 | −8.203 | Ala 602, Val 399, Lys 603, Gln 348, Ser 401, Ser 347 | NF |
| 6 | 16 ± 0.54 | 14 ± 0.16 | 15 ± 0.14 | 18 ± 0.54 | NF | NF | NF |
| 7 | 28 ± 0.32 | 25 ± 0.25 | 26 ± 0.28 | 24 ± 0.32 | −12.238 | Asp 354, Asp 354, Glu 488, Ala 602, Ser 401, Gln 348, Ser 303, Gly 301, Thr 352 | NF |
| 8 | 18 ± 0.18 | 16 ± 0.45 | 17 ± 0.36 | 15 ± 0.65 | −8.597 | Glu 488 | NF |
| 9 | 21 ± 0.23 | 19 ± 0.32 | 23 ± 0.23 | 24 ± 0.23 | −10.017 | Asp 354, Ala 602, Ala 602 | #Asp 354, #Asp 354 |
| 10 | 10 ± 0.56 | 09 ± 0.23 | 11 ± 0.65 | 12 ± 0.45 | NF | NF | NF |
| 11 | 16 ± 0.36 | 15 ± 0.55 | 17 ± 0.11 | 18 ± 0.78 | NF | NF | NF |
| 12 | 26 ± 0.65 | 24 ± 0.85 | 25 ± 0.45 | 27 ± 0.28 | −10.553 | Asp 354, Asp 354, Val 399, Cys 300, Ser 347, Ser 349, Ala 602, Asn 600 | NF |
| 13 | 18 ± 0.12 | 17 ± 0.35 | 19 ± 0.26 | 20 ± 0.45 | NF | NF | NF |
| 14 | 22 ± 0.26 | 20 ± 0.38 | 21 ± 0.65 | 22 ± 0.22 | −9.835 | Lys 603, Ser 303, Asp 354 | #Asp 354, #Asp 354 |
| 15 | 02 ± 0.35 | NA | 05 ± 0.32 | 01 ± 0.18 | −5.966 | Ala 602, Ala 602, Val 605, Thr 352, Ser 347, Ser 349, Gln 348, Ser 303 | NF |
| 16 | NA | 01 ± 0.08 | NA | 04 ± 0.26 | −5.816 | Ala 602, Thr 302, Ser 349, Ser 347 | NF |
| 17 | 04 ± 0.21 | 03 ± 0.21 | 05 ± 0.33 | 08 ± 0.21 | −7.199 | Ala 602, Ala 602, Leu 346, Cys 300, Gln 348, Ser 347, Lys 603, Lys 603 | NF |
| 18 | 05 ± 0.65 | NA | 07 ± 0.29 | NA | −7.170 | Ala 602, Ala 602, Cys 300, Ser 347, Ser 349, Gln 348, Ser 401, Ser 401, Ser 303 | NF |
| 19 | 14 ± 0.35 | 11 ± 0.65 | 13 ± 0.26 | 14 ± 0.29 | −8.083 | Gln 348, Val 399, Thr 302, Ala 602, Ser 401 | NF |
| 20 | 18 ± 0.16 | 16 ± 0.19 | 15 ± 0.32 | 16 ± 0.11 | −8.317 | Ala 602, Lys 603, Ser 303 | NF |
| 21 | 28 ± 0.22 | 26 ± 0.35 | 25 ± 0.24 | 24 ± 0.26 | −9.339 | Thr 352, Ser 303, Asn 600, Ala 602, Asn 305, Gly 301 | NF |
| 22 | 19 ± 0.32 | 20 ± 0.17 | 18 ± 0.35 | 17 ± 0.56 | −8.432 | Thr 352, Lys 603, Thr 302, Val 399, Ala 602 | NF |
| 23 | 22 ± 0.56 | 24 ± 0.29 | 21 ± 0.65 | 23 ± 0.36 | −8.969 | Thr 302, Gln 348, Ser 303, Ser 347, Thr 352 | #Glu 488 |
| 24 | 13 ± 0.25 | 10 ± 0.56 | 15 ± 0.36 | 14 ± 0.33 | NF | NF | NF |
| 25 | 16 ± 0.32 | 17 ± 0.44 | 18 ± 0.14 | 15 ± 0.38 | NF | NF | NF |
| 26 | 26 ± 0.35 | 22 ± 0.23 | 24 ± 0.36 | 25 ± 0.36 | −9.282 | Asn 305, Thr 352, Gln 348 | NF |
| 27 | 19 ± 0.26 | 16 ± 0.66 | 19 ± 0.56 | 20 ± 0.11 | NF | NF | NF |
| 28 | 24 ± 0.12 | 23 ± 0.33 | 24 ± 0.45 | 22 ± 0.65 | NF | NF | NF |
| SM | 15 ± 0.36 | 13 ± 0.69 | — | — | −9.517 | Gly 301, Asp 354, Asp 354, Cys 300, Thr 302, Ala 602, Ala 602, Glu 488 | #Glu 488 |
| BS | — | — | 14 ± 0.65 | 13 ± 0.36 | NF | NF | NF |
The values are the means of three determinations, the ranges of which are <5% of the mean in all cases, NF = not formed, SM = streptomycin, BS = bavistin.
Fig. 22D and 3D images of compounds 7, 12, 21 and 26 with 2HCK.
Fig. 32D and 3D images of compounds 9, 14, 23 and 28 with 1CX2.
Fig. 42D and 3D images of compounds 7, 9, 21 and 23 with 2VF5 protein.